GAMMA Investing LLC Boosts Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

GAMMA Investing LLC raised its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 11,580.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 161,538 shares of the company's stock after purchasing an additional 160,155 shares during the quarter. GAMMA Investing LLC owned 0.33% of Prestige Consumer Healthcare worth $13,887,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Prestige Consumer Healthcare in the 4th quarter worth $84,932,000. Raymond James Financial Inc. bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $42,593,000. Norges Bank purchased a new stake in Prestige Consumer Healthcare in the 4th quarter worth $40,009,000. Bessemer Group Inc. lifted its stake in Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock worth $23,041,000 after purchasing an additional 292,144 shares in the last quarter. Finally, Natixis Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 1,335.1% during the 4th quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock valued at $16,340,000 after purchasing an additional 194,665 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Finally, Royal Bank of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $93.33.

Prestige Consumer Healthcare Trading Up 1.1%

NYSE PBH traded up $0.91 during trading hours on Tuesday, hitting $86.59. 199,361 shares of the company were exchanged, compared to its average volume of 299,386. Prestige Consumer Healthcare Inc. has a 52 week low of $63.79 and a 52 week high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average price of $83.52 and a 200 day moving average price of $82.51. The stock has a market cap of $4.28 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 2.69 and a beta of 0.45.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The firm had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same quarter in the previous year, the company posted $1.02 EPS. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.